Obesity Management

Using data from more than 500 patients with more than 6 years of follow-up suggests total caloric intake may be more effective for reducing weight loss than increasing the time between meals.

A posthoc analysis of the VITAL study suggests the potential benefit of vitamin D supplementation could depend on a person's body mass index, with results indicating a decreased response to therapy as BMI category increased.

A secondary analysis of a cluster RCT indicated the Texas Sprouts intervention led to improvements in glucose control and reduced LDL-C in high-risk schoolchildren.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

Published in Pediatrics on January 9, the document represents the first comprehensive guideline from the American Academy of Pediatrics in more than a decade and the first ever on the evaluation and management of obesity in those aged 2 years and older.

Using data from 18 trials with more than 1400 participants, a systematic review and meta-analysis offer clinicians an overview of the effects of SGLT2 inhibitor use on body composition in people with type 2 diabetes.

Using data from more than 25,000 preschool-aged children in Sweden provides an overview in trends of weight gain and BMI changes that may have impacted pediatric populations during the COVID-19 pandemic.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The risk of cirrhosis increased supramultiplicatively in patients with obesity, with excessive drinking, and who were homozygous carriers.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

The inter-relationship of HPCs, HSCs, and macrophages was influenced by the stage of fibrosis, but not BMI.

A conversation on advancements in diabetes, the rising cost of insulin, and advice regarding disease management.

Early time-restricted eating was more effective for losing weight than eating over a window of ≥12 hours, but did not affect body fat.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The new recommendation acknowledges the role of disease-preventive behaviors that can be taken on by approximately 12% of the US population.

Trends in adjusted obesity prevalence increased over 20 years, particularly in adolescents from low-socioeconomic status households.

Preventable factors including obesity, hypertension, and physical activity are disparately impacting the rate of dementia among people of color.

Vaccine effectiveness was slightly lower in patients with underweight, who also have the lowest levels of vaccine uptake across all ages.

The approval, which was was supported by data from a 56-week trial involving 223 obese individuals 12-17 years old, recommended the capsules be used in conjunction with a reduced-calorie diet and increased physical activity.

A look into the top discussions on the management of obesity at the 2022 OMA Spring Meeting, from new agents to treating special populations.

Dr. Auriemma examines recent paradigm shifts in obesity care, from new pharmacotherapy options to the important role of stakeholders in reducing rates.

Data show the mean percentage change in weight at week 72 was -15.0% with 5-mg weekly doses of tirzepatide, -19.5% with 10-mg, and -20.9% with 15-mg dose, compared to -3.1% with placebo.

The findings are in contrast to previous research that suggests an inverse relationship between moderate-to-vigorous physical activity and HbA1c, TIR.

The FDA-approved sleep agent was associated with ≥5% weight loss in more than one-quarter of patients in a phase 3 trial.

The late-breaking findings at ADA 2022 suggest patients were more often prescribed oral semaglutide by primary care physicians than endocrinologists.

The diabetologist and professor discusses new findings from the ReTUNE trial, which disparage the utility of BMI in defining diabetes risk and remission opportunity.

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

New data from DDW 2022 show inpatient mortality rates were lower in patients with history of bariatric surgery.